Home › Companies › United Therapeutics Corporation › 2025-2026

United Therapeutics Corporation 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and United Therapeutics Corporation’s Form 8-K, filed June 29, 2026 (Item 5.07 on EDGAR). Page generated November 1, 2026.

15Ballot items
707Asset managers
11,576Fund votes
June 26, 2026Meeting date

Results at a glance

Meeting of June 26, 2026: 15 items on United Therapeutics Corporation’s Form 8-K, filed June 29, 2026: 15 without a stated outcome.

Material dissent

3. Approval of the United Therapeutics Corporation 2026 Stock Incentive Plan 72% of votes cast Outcome not stated Under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore United Therapeutics Corporation in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by United Therapeutics Corporation

These tallies are United Therapeutics Corporation’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 29, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

United Therapeutics Corporation — official shareholder meeting results, meeting held June 26, 2026
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Christopher Causey	32,342,983	3,861,566	14,328	--	1,194,857	89%	Not verified	—
Elect Director: Richard Giltner	33,029,828	3,174,662	14,387	--	1,194,857	91%	Not verified	—
Elect Director: Ray Kurzweil	35,215,793	988,979	14,105	--	1,194,857	97%	Not verified	—
Elect Director: Jan Malcolm	35,912,588	292,981	13,308	--	1,194,857	99.1%	Not verified	—
Elect Director: Linda Maxwell	35,472,607	725,977	20,293	--	1,194,857	98%	Not verified	—
Elect Director: Nilda Mesa	35,477,452	715,174	26,251	--	1,194,857	98%	Not verified	—
Elect Director: Judy Olian	35,661,334	543,343	14,200	--	1,194,857	98%	Not verified	—
Elect Director: Christopher Patusky	32,649,292	3,555,219	14,366	--	1,194,857	90%	Not verified	—
Elect Director: Martine Rothblatt	34,492,974	1,713,789	12,114	--	1,194,857	95%	Not verified	—
Elect Director: Louis Sullivan	33,409,607	2,794,332	14,938	--	1,194,857	92%	Not verified	—
Elect Director: Tommy Thompson	35,012,786	1,192,155	13,936	--	1,194,857	97%	Not verified	—
Elect Director: Kevin Tracey	36,187,554	18,239	13,084	--	1,194,857	99.9%	Not verified	—
2. An advisory resolution to approve executive compensation	35,152,059	1,048,505	18,313	--	1,194,857	97%	Not verified	—
3. Approval of the United Therapeutics Corporation 2026 Stock Incentive Plan	25,872,075	10,070,290	276,512	--	1,194,857	72%	Not verified	—
4. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2026	35,753,887	1,647,415	12,432	--	--	96%	Not verified	—

Source: United Therapeutics Corporation, Form 8-K, filed with the SEC on June 29, 2026 — read the filing on EDGAR.

How asset managers voted at the United Therapeutics Corporation 2025-2026 meeting

Each item below shows how the 707 asset managers that disclosed a United Therapeutics Corporation vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Christopher Causey

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%

FOR: 32,342,983AGAINST: 3,861,566

Details: description as filed, official tally, votes by 150 asset managers

Description as filed by funds: Election of Directors: Christopher Causey

United Therapeutics Corporation’s own tally for this item (“Elect Director: Christopher Causey”): 32,342,983 for, 3,861,566 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 150 asset managers below reported 14,356,801 for, 839,329 against, 9,058 abstained, 55 not voted.

FOR

FOR: 14,356,801AGAINST: 839,329ABSTAIN: 9,058NOT VOTED: 55

Largest asset managers voting on “Election of Directors: Christopher Causey” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Vote
Vanguard	5,078,166	3,197	For
BlackRock	2,961,581	0	For
Fidelity	1,516,671	0	For
Invesco	557,000	0	For
State Street	1,733	487,778	Against
Charles Schwab	295,879	0	For
Capitol Series Trust	275,236	0	For
Pacer Funds Trust	239,327	0	For
Lord Abbett	230,372	0	For
First Trust	229,981	0	For
JANUS INVESTMENT FUND	227,058	0	For
T. Rowe Price	222,443	0	For
Franklin Custodian Funds	200,000	0	For
Dimensional	177,305	0	For
TIAA	0	155,920	Against
Hartford	142,361	0	For
John Hancock	134,710	0	For
Thrivent	111,740	0	For
JPMorgan	99,481	0	For
Jackson National	7,428	74,136	Mixed
AQR	73,127	0	For
ADVISORS SERIES TRUST	70,900	0	For
TOCQUEVILLE ASSET MANAGEMENT L.P.	70,900	0	For
American Century	66,480	0	For
Equitable	66,260	0	For

Showing the 25 largest of 150 asset managers. See all 150 in the interactive database.

2. Elect Director: Christopher Patusky

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%

FOR: 32,649,292AGAINST: 3,555,219

Details: description as filed, official tally, votes by 150 asset managers

Description as filed by funds: Election of Directors: Christopher Patusky

United Therapeutics Corporation’s own tally for this item (“Elect Director: Christopher Patusky”): 32,649,292 for, 3,555,219 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 150 asset managers below reported 14,662,623 for, 533,506 against, 9,058 abstained, 55 not voted.

FOR

FOR: 14,662,623AGAINST: 533,506ABSTAIN: 9,058NOT VOTED: 55

Largest asset managers voting on “Election of Directors: Christopher Patusky” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Vote
Vanguard	5,081,350	12	For
BlackRock	2,961,581	0	For
Fidelity	1,516,671	0	For
Invesco	557,000	0	For
State Street	1,733	487,778	Against
Charles Schwab	295,879	0	For
Capitol Series Trust	275,236	0	For
Pacer Funds Trust	239,327	0	For
Lord Abbett	230,372	0	For
First Trust	229,981	0	For
JANUS INVESTMENT FUND	227,058	0	For
T. Rowe Price	222,443	0	For
Franklin Custodian Funds	200,000	0	For
Dimensional	177,305	0	For
TIAA	155,920	0	For
Hartford	142,361	0	For
John Hancock	134,710	0	For
Thrivent	111,740	0	For
JPMorgan	99,481	0	For
Jackson National	81,564	0	For
AQR	73,127	0	For
ADVISORS SERIES TRUST	70,900	0	For
TOCQUEVILLE ASSET MANAGEMENT L.P.	70,900	0	For
American Century	66,480	0	For
Equitable	66,260	0	For

Showing the 25 largest of 150 asset managers. See all 150 in the interactive database.

3. Elect Director: Jan Malcolm

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%

FOR: 35,912,588AGAINST: 292,981

Details: description as filed, official tally, votes by 150 asset managers

Description as filed by funds: Election of Directors: Jan Malcolm

United Therapeutics Corporation’s own tally for this item (“Elect Director: Jan Malcolm”): 35,912,588 for, 292,981 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 150 asset managers below reported 15,191,449 for, 4,681 against, 9,058 abstained, 55 not voted.

FOR

FOR: 15,191,449AGAINST: 4,681ABSTAIN: 9,058NOT VOTED: 55

Largest asset managers voting on “Election of Directors: Jan Malcolm” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Vote
Vanguard	5,081,362	1	For
BlackRock	2,961,581	0	For
Fidelity	1,516,671	0	For
Invesco	557,000	0	For
State Street	489,511	0	For
Charles Schwab	295,879	0	For
Capitol Series Trust	275,236	0	For
Pacer Funds Trust	239,327	0	For
Lord Abbett	230,372	0	For
First Trust	229,981	0	For
JANUS INVESTMENT FUND	227,058	0	For
T. Rowe Price	222,443	0	For
Franklin Custodian Funds	200,000	0	For
Dimensional	177,305	0	For
TIAA	155,920	0	For
Hartford	142,361	0	For
John Hancock	134,710	0	For
Thrivent	111,740	0	For
JPMorgan	99,481	0	For
Jackson National	81,564	0	For
AQR	73,127	0	For
ADVISORS SERIES TRUST	70,900	0	For
TOCQUEVILLE ASSET MANAGEMENT L.P.	70,900	0	For
American Century	66,480	0	For
Equitable	66,260	0	For

Showing the 25 largest of 150 asset managers. See all 150 in the interactive database.

4. Elect Director: Judy Olian

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 35,661,334AGAINST: 543,343

Details: description as filed, official tally, votes by 150 asset managers

Description as filed by funds: Election of Directors: Judy Olian

United Therapeutics Corporation’s own tally for this item (“Elect Director: Judy Olian”): 35,661,334 for, 543,343 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 150 asset managers below reported 15,180,218 for, 15,912 against, 9,058 abstained, 55 not voted.

FOR

FOR: 15,180,218AGAINST: 15,912ABSTAIN: 9,058NOT VOTED: 55

Largest asset managers voting on “Election of Directors: Judy Olian” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Vote
Vanguard	5,081,361	2	For
BlackRock	2,961,581	0	For
Fidelity	1,516,671	0	For
Invesco	557,000	0	For
State Street	489,487	24	For
Charles Schwab	295,879	0	For
Capitol Series Trust	275,236	0	For
Pacer Funds Trust	239,327	0	For
Lord Abbett	230,372	0	For
First Trust	229,981	0	For
JANUS INVESTMENT FUND	227,058	0	For
T. Rowe Price	222,443	0	For
Franklin Custodian Funds	200,000	0	For
Dimensional	177,305	0	For
TIAA	155,920	0	For
Hartford	142,361	0	For
John Hancock	134,710	0	For
Thrivent	111,740	0	For
JPMorgan	99,481	0	For
Jackson National	81,564	0	For
AQR	73,127	0	For
ADVISORS SERIES TRUST	70,900	0	For
TOCQUEVILLE ASSET MANAGEMENT L.P.	70,900	0	For
American Century	66,480	0	For
Equitable	66,260	0	For

Showing the 25 largest of 150 asset managers. See all 150 in the interactive database.

5. Elect Director: Kevin Tracey

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 36,187,554AGAINST: 18,239

Details: description as filed, official tally, votes by 150 asset managers

Description as filed by funds: Election of Directors: Kevin Tracey

United Therapeutics Corporation’s own tally for this item (“Elect Director: Kevin Tracey”): 36,187,554 for, 18,239 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 150 asset managers below reported 15,191,450 for, 4,680 against, 9,058 abstained, 55 not voted.

FOR

FOR: 15,191,450AGAINST: 4,680ABSTAIN: 9,058NOT VOTED: 55

Largest asset managers voting on “Election of Directors: Kevin Tracey” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Vote
Vanguard	5,081,363	For
BlackRock	2,961,581	For
Fidelity	1,516,671	For
Invesco	557,000	For
State Street	489,511	For
Charles Schwab	295,879	For
Capitol Series Trust	275,236	For
Pacer Funds Trust	239,327	For
Lord Abbett	230,372	For
First Trust	229,981	For
JANUS INVESTMENT FUND	227,058	For
T. Rowe Price	222,443	For
Franklin Custodian Funds	200,000	For
Dimensional	177,305	For
TIAA	155,920	For
Hartford	142,361	For
John Hancock	134,710	For
Thrivent	111,740	For
JPMorgan	99,481	For
Jackson National	81,564	For
AQR	73,127	For
ADVISORS SERIES TRUST	70,900	For
TOCQUEVILLE ASSET MANAGEMENT L.P.	70,900	For
American Century	66,480	For
Equitable	66,260	For

Showing the 25 largest of 150 asset managers. See all 150 in the interactive database.

6. Elect Director: Linda Maxwell

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 35,472,607AGAINST: 725,977

Details: description as filed, official tally, votes by 150 asset managers

Description as filed by funds: Election of Directors: Linda Maxwell

United Therapeutics Corporation’s own tally for this item (“Elect Director: Linda Maxwell”): 35,472,607 for, 725,977 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 150 asset managers below reported 15,173,123 for, 23,007 against, 9,058 abstained, 55 not voted.

FOR

FOR: 15,173,123AGAINST: 23,007ABSTAIN: 9,058NOT VOTED: 55

Largest asset managers voting on “Election of Directors: Linda Maxwell” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Vote
Vanguard	5,081,361	2	For
BlackRock	2,961,581	0	For
Fidelity	1,516,671	0	For
Invesco	557,000	0	For
State Street	489,511	0	For
Charles Schwab	295,879	0	For
Capitol Series Trust	275,236	0	For
Pacer Funds Trust	239,327	0	For
Lord Abbett	230,372	0	For
First Trust	229,981	0	For
JANUS INVESTMENT FUND	227,058	0	For
T. Rowe Price	222,443	0	For
Franklin Custodian Funds	200,000	0	For
Dimensional	177,305	0	For
TIAA	155,920	0	For
Hartford	142,361	0	For
John Hancock	134,710	0	For
Thrivent	111,740	0	For
JPMorgan	99,481	0	For
Jackson National	81,564	0	For
AQR	73,127	0	For
ADVISORS SERIES TRUST	70,900	0	For
TOCQUEVILLE ASSET MANAGEMENT L.P.	70,900	0	For
American Century	66,480	0	For
Equitable	66,260	0	For

Showing the 25 largest of 150 asset managers. See all 150 in the interactive database.

7. Elect Director: Louis Sullivan

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%

FOR: 33,409,607AGAINST: 2,794,332

Details: description as filed, official tally, votes by 150 asset managers

Description as filed by funds: Election of Directors: Louis Sullivan

United Therapeutics Corporation’s own tally for this item (“Elect Director: Louis Sullivan”): 33,409,607 for, 2,794,332 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 150 asset managers below reported 14,679,723 for, 516,407 against, 9,058 abstained, 55 not voted.

FOR

FOR: 14,679,723AGAINST: 516,407ABSTAIN: 9,058NOT VOTED: 55

Largest asset managers voting on “Election of Directors: Louis Sullivan” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Vote
Vanguard	5,081,352	11	For
BlackRock	2,961,581	0	For
Fidelity	1,516,671	0	For
Invesco	557,000	0	For
State Street	1,733	487,778	Against
Charles Schwab	295,879	0	For
Capitol Series Trust	275,236	0	For
Pacer Funds Trust	239,327	0	For
Lord Abbett	230,372	0	For
First Trust	229,981	0	For
JANUS INVESTMENT FUND	227,058	0	For
T. Rowe Price	222,443	0	For
Franklin Custodian Funds	200,000	0	For
Dimensional	177,305	0	For
TIAA	155,920	0	For
Hartford	142,361	0	For
John Hancock	134,710	0	For
Thrivent	111,740	0	For
JPMorgan	99,481	0	For
Jackson National	81,564	0	For
AQR	73,127	0	For
ADVISORS SERIES TRUST	70,900	0	For
TOCQUEVILLE ASSET MANAGEMENT L.P.	70,900	0	For
American Century	66,480	0	For
Equitable	66,260	0	For

Showing the 25 largest of 150 asset managers. See all 150 in the interactive database.

8. Elect Director: Martine Rothblatt

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 34,492,974AGAINST: 1,713,789

Details: description as filed, official tally, votes by 150 asset managers

Description as filed by funds: Election of Directors: Martine Rothblatt

United Therapeutics Corporation’s own tally for this item (“Elect Director: Martine Rothblatt”): 34,492,974 for, 1,713,789 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 150 asset managers below reported 15,140,493 for, 55,637 against, 9,058 abstained, 55 not voted.

FOR

FOR: 15,140,493AGAINST: 55,637ABSTAIN: 9,058NOT VOTED: 55

Largest asset managers voting on “Election of Directors: Martine Rothblatt” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Vote
Vanguard	5,081,357	6	For
BlackRock	2,961,581	0	For
Fidelity	1,516,671	0	For
Invesco	557,000	0	For
State Street	489,487	24	For
Charles Schwab	295,879	0	For
Capitol Series Trust	275,236	0	For
Pacer Funds Trust	239,327	0	For
Lord Abbett	230,372	0	For
First Trust	229,981	0	For
JANUS INVESTMENT FUND	227,058	0	For
T. Rowe Price	222,443	0	For
Franklin Custodian Funds	200,000	0	For
Dimensional	177,305	0	For
TIAA	155,920	0	For
Hartford	142,361	0	For
John Hancock	99,589	35,121	Mixed
Thrivent	111,740	0	For
JPMorgan	99,481	0	For
Jackson National	81,564	0	For
AQR	73,127	0	For
ADVISORS SERIES TRUST	70,900	0	For
TOCQUEVILLE ASSET MANAGEMENT L.P.	70,900	0	For
American Century	66,480	0	For
Equitable	66,260	0	For

Showing the 25 largest of 150 asset managers. See all 150 in the interactive database.

9. Elect Director: Nilda Mesa

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 35,477,452AGAINST: 715,174

Details: description as filed, official tally, votes by 150 asset managers

Description as filed by funds: Election of Directors: Nilda Mesa

United Therapeutics Corporation’s own tally for this item (“Elect Director: Nilda Mesa”): 35,477,452 for, 715,174 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 150 asset managers below reported 15,173,123 for, 23,007 against, 9,058 abstained, 55 not voted.

FOR

FOR: 15,173,123AGAINST: 23,007ABSTAIN: 9,058NOT VOTED: 55

Largest asset managers voting on “Election of Directors: Nilda Mesa” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Vote
Vanguard	5,081,361	2	For
BlackRock	2,961,581	0	For
Fidelity	1,516,671	0	For
Invesco	557,000	0	For
State Street	489,511	0	For
Charles Schwab	295,879	0	For
Capitol Series Trust	275,236	0	For
Pacer Funds Trust	239,327	0	For
Lord Abbett	230,372	0	For
First Trust	229,981	0	For
JANUS INVESTMENT FUND	227,058	0	For
T. Rowe Price	222,443	0	For
Franklin Custodian Funds	200,000	0	For
Dimensional	177,305	0	For
TIAA	155,920	0	For
Hartford	142,361	0	For
John Hancock	134,710	0	For
Thrivent	111,740	0	For
JPMorgan	99,481	0	For
Jackson National	81,564	0	For
AQR	73,127	0	For
ADVISORS SERIES TRUST	70,900	0	For
TOCQUEVILLE ASSET MANAGEMENT L.P.	70,900	0	For
American Century	66,480	0	For
Equitable	66,260	0	For

Showing the 25 largest of 150 asset managers. See all 150 in the interactive database.

10. Elect Director: Ray Kurzweil

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 35,215,793AGAINST: 988,979

Details: description as filed, official tally, votes by 150 asset managers

Description as filed by funds: Election of Directors: Ray Kurzweil

United Therapeutics Corporation’s own tally for this item (“Elect Director: Ray Kurzweil”): 35,215,793 for, 988,979 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 150 asset managers below reported 15,188,903 for, 7,227 against, 9,058 abstained, 55 not voted.

FOR

FOR: 15,188,903AGAINST: 7,227ABSTAIN: 9,058NOT VOTED: 55

Largest asset managers voting on “Election of Directors: Ray Kurzweil” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Vote
Vanguard	5,081,359	4	For
BlackRock	2,961,581	0	For
Fidelity	1,516,671	0	For
Invesco	557,000	0	For
State Street	489,487	24	For
Charles Schwab	295,879	0	For
Capitol Series Trust	275,236	0	For
Pacer Funds Trust	239,327	0	For
Lord Abbett	230,372	0	For
First Trust	229,981	0	For
JANUS INVESTMENT FUND	227,058	0	For
T. Rowe Price	222,443	0	For
Franklin Custodian Funds	200,000	0	For
Dimensional	177,305	0	For
TIAA	155,920	0	For
Hartford	142,361	0	For
John Hancock	134,710	0	For
Thrivent	111,740	0	For
JPMorgan	99,481	0	For
Jackson National	81,564	0	For
AQR	73,127	0	For
ADVISORS SERIES TRUST	70,900	0	For
TOCQUEVILLE ASSET MANAGEMENT L.P.	70,900	0	For
American Century	66,480	0	For
Equitable	66,260	0	For

Showing the 25 largest of 150 asset managers. See all 150 in the interactive database.

11. Elect Director: Richard Giltner

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%

FOR: 33,029,828AGAINST: 3,174,662

Details: description as filed, official tally, votes by 150 asset managers

Description as filed by funds: Election of Directors: Richard Giltner

United Therapeutics Corporation’s own tally for this item (“Elect Director: Richard Giltner”): 33,029,828 for, 3,174,662 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 150 asset managers below reported 14,660,735 for, 535,395 against, 9,058 abstained, 55 not voted.

FOR

FOR: 14,660,735AGAINST: 535,395ABSTAIN: 9,058NOT VOTED: 55

Largest asset managers voting on “Election of Directors: Richard Giltner” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Vote
Vanguard	5,078,170	3,193	For
BlackRock	2,961,581	0	For
Fidelity	1,516,671	0	For
Invesco	557,000	0	For
State Street	1,733	487,778	Against
Charles Schwab	295,879	0	For
Capitol Series Trust	275,236	0	For
Pacer Funds Trust	239,327	0	For
Lord Abbett	230,372	0	For
First Trust	229,981	0	For
JANUS INVESTMENT FUND	227,058	0	For
T. Rowe Price	222,443	0	For
Franklin Custodian Funds	200,000	0	For
Dimensional	177,305	0	For
TIAA	155,920	0	For
Hartford	142,361	0	For
John Hancock	134,710	0	For
Thrivent	111,740	0	For
JPMorgan	99,481	0	For
Jackson National	81,564	0	For
AQR	73,127	0	For
ADVISORS SERIES TRUST	70,900	0	For
TOCQUEVILLE ASSET MANAGEMENT L.P.	70,900	0	For
American Century	66,480	0	For
Equitable	66,260	0	For

Showing the 25 largest of 150 asset managers. See all 150 in the interactive database.

12. Elect Director: Tommy Thompson

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 35,012,786AGAINST: 1,192,155

Details: description as filed, official tally, votes by 150 asset managers

Description as filed by funds: Election of Directors: Tommy Thompson

United Therapeutics Corporation’s own tally for this item (“Elect Director: Tommy Thompson”): 35,012,786 for, 1,192,155 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 150 asset managers below reported 15,177,216 for, 18,914 against, 9,058 abstained, 55 not voted.

FOR

FOR: 15,177,216AGAINST: 18,914ABSTAIN: 9,058NOT VOTED: 55

Largest asset managers voting on “Election of Directors: Tommy Thompson” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Vote
Vanguard	5,081,359	4	For
BlackRock	2,961,581	0	For
Fidelity	1,516,671	0	For
Invesco	557,000	0	For
State Street	489,487	24	For
Charles Schwab	295,879	0	For
Capitol Series Trust	275,236	0	For
Pacer Funds Trust	239,327	0	For
Lord Abbett	230,372	0	For
First Trust	229,981	0	For
JANUS INVESTMENT FUND	227,058	0	For
T. Rowe Price	222,443	0	For
Franklin Custodian Funds	200,000	0	For
Dimensional	177,305	0	For
TIAA	155,920	0	For
Hartford	142,361	0	For
John Hancock	134,710	0	For
Thrivent	111,740	0	For
JPMorgan	99,481	0	For
Jackson National	81,564	0	For
AQR	73,127	0	For
ADVISORS SERIES TRUST	70,900	0	For
TOCQUEVILLE ASSET MANAGEMENT L.P.	70,900	0	For
American Century	66,480	0	For
Equitable	66,260	0	For

Showing the 25 largest of 150 asset managers. See all 150 in the interactive database.

13. 3. Approval of the United Therapeutics Corporation 2026 Stock Incentive Plan

Outcome not verified Fund totals may overlapCOMPENSATIONReported outcome: Not verified

Combines 6 wordings of this item as funds reported it.

72% Majority: yes · of votes cast

FOR 72%AGAINST

FOR: 25,872,075AGAINST: 10,070,290

Details: description as filed, official tally, votes by 183 asset managers

Description as filed by funds: Approval of the United Therapeutics Corporation 2026 Stock Incentive Plan.

United Therapeutics Corporation’s own tally for this item (“3. Approval of the United Therapeutics Corporation 2026 Stock Incentive Plan”): 25,872,075 for, 10,070,290 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 72% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 145 asset managers voting on “Approval of the United Therapeutics Corporation 2026 Stock Incentive Plan.” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	5,080,806	557	1	For
BlackRock	2,961,581	0	0	For
Fidelity	1,456,281	60,390	0	For
Invesco	557,000	0	0	For
State Street	488,964	547	0	For
Charles Schwab	295,879	0	0	For
Capitol Series Trust	3,500	271,736	0	Against
Pacer Funds Trust	0	239,327	0	Against
Lord Abbett	230,372	0	0	For
First Trust	0	229,981	0	Against
JANUS INVESTMENT FUND	227,058	0	0	For
T. Rowe Price	215,343	7,100	0	For
Franklin Custodian Funds	200,000	0	0	For
Dimensional	0	177,305	0	Against
TIAA	155,920	0	0	For
Hartford	142,361	0	0	For
John Hancock	80,606	54,104	0	Mixed
Thrivent	0	111,740	0	Against
JPMorgan	99,481	0	0	For
Jackson National	74,136	7,428	0	Mixed
AQR	0	73,127	0	Against
ADVISORS SERIES TRUST	0	70,900	0	Against
American Century	0	66,480	0	Against
Equitable	66,260	0	0	For
Brighthouse	48,135	15,801	0	Mixed

Fund voting reports, all 145 managers: 13,182,911 for, 1,904,238 against, 1 abstained, 55 not voted. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 37 asset managers voting on “Approval of the United Therapeutics Corporation 2026 Stock Incentive Plan.” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Abstain	Vote
Eversept Partners, LP	0	0	257,947	Abstain
BOWEN HANES & CO INC	114,460	0	0	For
TOCQUEVILLE ASSET MANAGEMENT L.P.	0	70,900	0	Against
Erste Asset Management GmbH	0	27,009	0	Against
Cardano Risk Management B.V.	15,806	0	0	For
L2 Asset Management, LLC	14,005	0	0	For
Apollon Wealth Management, LLC	8,744	0	0	For
Vident Advisory, LLC	5,494	0	0	For
Dorsey Wright & Associates	0	4,810	0	Against
EVOLVE PRIVATE WEALTH, LLC	4,746	0	0	For
AUGUSTINE ASSET MANAGEMENT INC	4,151	0	0	For
LEUTHOLD GROUP, LLC	2,937	0	0	For
Clark Capital Management Group, Inc.	2,027	0	0	For
Trail Ridge Investment Advisors, LLC	1,620	0	0	For
Summit Trail Advisors, LLC	0	747	0	Against
UNITED CAPITAL FINANCIAL ADVISORS, LLC	0	519	0	Against
Hendershot Investments Inc.	0	200	0	Against
ZACKS INVESTMENT MANAGEMENT	14	147	0	Mixed
WRIGHT INVESTORS SERVICE INC	106	0	0	For
Royal Capital Wealth Management, LLC	103	0	0	For
Sound View Wealth Advisors Group, LLC	100	0	0	For
Empirical Asset Management, LLC	93	0	0	For
Holcombe Financial, Inc.	0	60	0	Against
Biltmore Family Office, LLC	27	0	0	For
Keel Point, LLC	0	25	0	Against

Institutional-manager reports, all 37 managers: 174,558 for, 104,417 against, 257,947 abstained, 7 unknown. Showing the 25 largest; see all in the interactive database.

14. 2. An advisory resolution to approve executive compensation

Outcome not verified Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Not verified

Combines 12 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 35,152,059AGAINST: 1,048,505

Details: description as filed, official tally, votes by 704 asset managers

Description as filed by funds: Advisory resolution to approve executive compensation.

United Therapeutics Corporation’s own tally for this item (“2. An advisory resolution to approve executive compensation”): 35,152,059 for, 1,048,505 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Also reported under other wordings, matched to the same row of United Therapeutics Corporation’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Compensation” (2 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).

Fund voting reports: 146 asset managers voting on “Advisory resolution to approve executive compensation.” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	5,081,360	2	0	For
BlackRock	2,961,581	0	0	For
Fidelity	1,516,671	0	0	For
Invesco	557,000	0	0	For
State Street	489,511	0	0	For
Charles Schwab	295,879	0	0	For
Capitol Series Trust	275,236	0	0	For
Pacer Funds Trust	239,327	0	0	For
Lord Abbett	230,372	0	0	For
First Trust	229,981	0	0	For
JANUS INVESTMENT FUND	227,058	0	0	For
T. Rowe Price	215,343	7,100	0	For
Franklin Custodian Funds	200,000	0	0	For
Dimensional	177,305	0	0	For
TIAA	155,920	0	0	For
Hartford	142,361	0	0	For
John Hancock	134,710	0	0	For
Thrivent	111,740	0	0	For
JPMorgan	99,481	0	0	For
Jackson National	76,503	5,061	0	Mixed
AQR	73,127	0	0	For
ADVISORS SERIES TRUST	70,900	0	0	For
American Century	0	66,480	0	Against
Equitable	66,260	0	0	For
Brighthouse	54,878	0	9,058	Mixed

Fund voting reports, all 146 managers: 14,987,550 for, 106,629 against, 9,058 abstained, 55 not voted, 27 mixed. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 588 asset managers voting on “Advisory resolution to approve executive compensation.” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Vote
Avoro Capital Advisors LLC	1,950,083	0	For
BlackRock	1,860,402	293	For
Wellington	1,702,773	0	For
State Street	1,674,813	0	For
Renaissance	1,297,762	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,228,214	0	For
Janus Henderson	1,085,928	0	For
Invesco	611,180	0	For
ASSETMARK, INC	497,982	60	For
Fidelity	496,630	0	For
DEERFIELD MANAGEMENT COMPANY, L.P.	457,000	0	For
AQR	384,147	0	For
T. Rowe Price	345,449	15,310	For
Northern Trust	345,524	0	For
Vanguard	333,642	0	For
MELLON INVESTMENTS Corp	329,823	0	For
CAISSE DE DEPOT ET PLACEMENT DU QUEBEC	318,225	0	For
Swedbank Robur Fonder AB	314,514	0	For
BAILLIE GIFFORD OVERSEAS LTD	305,326	0	For
Charles Schwab	301,898	0	For
FULLER & THALER ASSET MANAGEMENT, INC.	284,237	0	For
LORD, ABBETT & CO. LLC	264,933	0	For
PICTET ASSET MANAGEMENT SA	259,314	0	For
Eversept Partners, LP	257,947	0	For
FRANKLIN ADVISERS INC	234,576	0	For

Institutional-manager reports, all 588 managers: 24,162,628 for, 754,137 against, 1,357 abstained, 6,559 not voted. Showing the 25 largest; see all in the interactive database.

15. 4. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm…

Outcome not verifiedAUDIT-RELATEDReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 35,753,887AGAINST: 1,647,415

Details: description as filed, official tally, votes by 149 asset managers

Description as filed by funds: Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2026.

United Therapeutics Corporation’s own tally for this item (“4. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2026”): 35,753,887 for, 1,647,415 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 149 asset managers below reported 15,168,787 for, 12,048 against, 9,058 abstained, 55 not voted.

FOR

FOR: 15,168,787AGAINST: 12,048ABSTAIN: 9,058NOT VOTED: 55

Largest asset managers voting on “Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for ” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Vote
Vanguard	5,078,175	3,188	For
BlackRock	2,961,581	0	For
Fidelity	1,516,671	0	For
Invesco	557,000	0	For
State Street	489,487	24	For
Charles Schwab	295,879	0	For
Capitol Series Trust	275,236	0	For
Pacer Funds Trust	239,327	0	For
Lord Abbett	230,372	0	For
First Trust	229,981	0	For
JANUS INVESTMENT FUND	227,058	0	For
T. Rowe Price	222,443	0	For
Franklin Custodian Funds	200,000	0	For
Dimensional	177,305	0	For
TIAA	155,920	0	For
Hartford	142,361	0	For
John Hancock	134,710	0	For
Thrivent	111,740	0	For
JPMorgan	99,481	0	For
Jackson National	81,564	0	For
AQR	73,127	0	For
ADVISORS SERIES TRUST	70,900	0	For
TOCQUEVILLE ASSET MANAGEMENT L.P.	70,900	0	For
American Century	66,480	0	For
Equitable	66,260	0	For

Showing the 25 largest of 149 asset managers. See all 149 in the interactive database.

Not shown here: this season’s fund filings also report 1 item from the meeting of June 26, 2025, which belongs to the 2024-2025 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.

Largest United Therapeutics Corporation shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 42,446,733 shares outstanding at the time of that meeting.

Fund voting reports: top United Therapeutics Corporation shareholders by shares voted on “Advisory resolution to approve executive compensation.”, 2025-2026
#	Asset manager	% of shares outstanding
1	Vanguard	11.97%
2	BlackRock	6.98%
3	Fidelity	3.57%
4	Invesco	1.31%
5	State Street	1.15%
6	Charles Schwab	0.70%
7	Capitol Series Trust	0.65%
8	Pacer Funds Trust	0.56%
9	Lord Abbett	0.54%
10	First Trust	0.54%

Institutional-manager reports: top United Therapeutics Corporation shareholders by shares voted on “Advisory resolution to approve executive compensation.”, 2025-2026
#	Asset manager	% of shares outstanding
1	Avoro Capital Advisors LLC	4.59%
2	BlackRock	4.38%
3	Wellington	4.01%
4	State Street	3.95%
5	Renaissance	3.06%
6	GEODE CAPITAL MANAGEMENT, LLC	2.89%
7	Janus Henderson	2.56%
8	Invesco	1.44%
9	ASSETMARK, INC	1.17%
10	Fidelity	1.17%

Reported United Therapeutics Corporation holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

United Therapeutics Corporation holdings and ownership disclosed for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
BlackRock	12.72%	13F
Vanguard Group	9.84%	13F
Martine Rothblatt	6.76%	DEF14A
Avoro Capital Advisors LLC	6.74%	DEF14A
ROTHBLATT MARTINE A	5.50%	13G
Wellington Management	5.33%	13F
State Street	4.34%	13F
Renaissance Technologies	4.21%	13F
Citadel Advisors	1.64%	13F
Invesco	1.43%	13F

Percentages above are of 42,446,733 shares outstanding, as reported by United Therapeutics Corporation on its Form 10-Q dated April 29, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from United Therapeutics Corporation’s 10-Q dated April 29, 2026. This page is a static snapshot rebuilt weekly on November 1, 2026; a live search always shows the current data.

At United Therapeutics Corporation's shareholder meeting held June 26, 2026, in the 2025-2026 proxy season, 707 asset managers reported how they voted on 15 ballot items in their SEC Form N-PX filings, covering 11,576 separate fund positions. On the most widely held item on that ballot — Advisory resolution to approve executive compensation. — FOR was 97% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: United Therapeutics Corporation's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 29, 2026.

United Therapeutics Corporation proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Download data (CSV): ballot items · votes by manager · column guide.